Supply Chain Intelligence

XOMA Royalty Corporation Supply Chain

XOMA supply chain intelligence for XOMA Royalty Corporation: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

XOMA ·Last updated 2026-09-13 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

19Suppliers
28Customers
3Debt Items
20Related Chains

Source-Backed Evidence Depth

XOMA Royalty Corporation (XOMA) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

53Total relationships
3Distinct source URLs
30High confidence
0.810Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

XOMA Royalty Corporation Suppliers

TickerNameConfidenceEvidence
AFFITECH-RESEARCH-AS AFFITECH-RESEARCH-AS 92% The Company's Commercial Payment Purchase Agreement with Affitech dated October 6, 2021
AGENUS-INC AGENUS-INC 92% The Company's Royalty Purchase Agreement with Agenus dated September 20, 2018
APTEVO-THERAPEUTICS-INC APTEVO-THERAPEUTICS-INC 92% The Company’s Payment Interest Purchase Agreement with Aptevo dated March 29, 2023
ARONORA-INC ARONORA-INC 92% The Company's Royalty Purchase Agreement with Aronora dated April 7, 2019
BIOASIS-TECHNOLOGIES-INC BIOASIS-TECHNOLOGIES-INC 92% The Company's Royalty Purchase Agreement with Bioasis dated February 25, 2019
CASTLE-CREEK-BIOSCIENCES-INC CASTLE-CREEK-BIOSCIENCES-INC 92% The Company’s Royalty Purchase Agreement with Castle Creek dated February 24, 2025
CHECKMATE-PHARMACEUTICALS-INC CHECKMATE-PHARMACEUTICALS-INC 92% The Company’s Commercial Payment Purchase Agreement with Affitech dated October 6, 2021
DAR-BIOSCIENCE-INC DAR-BIOSCIENCE-INC 92% The Company’s Traditional Royalty Purchase Agreement and Synthetic Royalty Purchase Agreement, both with Daré dated April 29, 2024
DAY-ONE-BIOPHARMACEUTICALS-INC DAY-ONE-BIOPHARMACEUTICALS-INC 92% License Agreement for RAF between Viracta and Day One dated December 16, 2019
IMMUNITYBIO-INC IMMUNITYBIO-INC 92% Out-license agreement to ImmunityBio from LadRx dated July 27, 2017
KUROS-BIOSCIENCES-AG KUROS-BIOSCIENCES-AG 92% The Company's Royalty Purchase Agreement with Kuros dated July 14, 2021
LADX LadRx Corporation 92% Reciprocal relationship from LADX graph: Reciprocal relationship from XOMA graph: The Company’s Assignment and Assumption Agreement with LadRx
LADX LadRx Corporation 92% The Company’s Assignment and Assumption Agreement with LadRx
CASTLE-CREEK CASTLE-CREEK 90% Upon the closing of the transaction, the Company paid Castle Creek an upfront payment of $ 5.0 million and recorded $ 4.4 million as long-term royalty and commercial payment receivables
GENERATION-BIO GENERATION-BIO 90% XOMA Royalty does not have plans to continue any preclinical development of the Legacy Assets or integrate Generation Bio's legacy business into its own.
MODERNATX-INC MODERNATX-INC 90% Under the terms of the Moderna Agreement, Moderna is responsible for the development, manufacturing, and commercialization of products comprising LNP delivery systems and nucleic acid payloads
BROADRIDGE-CORPORATE-ISSUER-SOLUTIONS-LLC BROADRIDGE-CORPORATE-ISSUER-SOLUTIONS-LLC 85% Contingent Value Rights Agreement, dated February 9, 2026, by and among XOMA Royalty Corporation, XRA 7 Corp., and Broadridge Corporate Issuer Solutions, LLC
BLUE-OWL BLUE-OWL 80% Long-term debt represents the Company’s term loan under the Blue Owl Loan Agreement, which the Company has accounted for as a debt financing arrangement
MNPR Monopar Therapeutics Inc. 62% Reciprocal relationship from MNPR graph: e year ended December 31, 2024 , was primarily related to the payment of $3 million in 2025 related to the in-licensing of ALXN1840. Cash Flow Used in Investi…

XOMA Royalty Corporation Customers

TickerNameConfidenceEvidence
GENERATION-BIO GENERATION-BIO 92% XOMA Royalty completed the acquisition of Generation Bio on February 9, 2026, by causing Merger Sub to merge with and into Generation Bio
RZLT Rezolute, Inc. 92% Reciprocal relationship from RZLT graph: The Company will be required, upon the future commercialization of ersodetug, to pay royalties to XOMA based on the net sales of the related products and addi…
LADX LadRx Corporation 90% Reciprocal relationship from LADX graph: the Company agreed to sell, transfer, assign and convey to XOMA, among other payments, all royalty payments and regulatory and commercial milestone payments p…
KUROS KUROS 85% the Company acquired the rights to 100 % of the potential future royalties from Kuros
MODERNATX-INC MODERNATX-INC 85% Under the terms of the Moderna Agreement, Moderna is responsible for the development, manufacturing, and commercialization of products comprising LNP delivery systems and nucleic acid payloads.
MNPR Monopar Therapeutics Inc. 80% Reciprocal relationship from MNPR graph: Reciprocal relationship from XOMA graph: Reciprocal relationship from MNPR graph: We also rely on certain rights to MNPR-101 that we have secured through a no…
DARE Daré Bioscience, Inc. 72% Reciprocal relationship from DARE graph: Reciprocal relationship from XOMA graph: Reciprocal relationship from DARE graph: Reciprocal relationship from XOMA graph: Item 4. ​ Mine Safety Disclosures ​…
DARE Daré Bioscience, Inc. 72% Item 4. ​ Mine Safety Disclosures ​ 70 ​ ​ ​ ​ ​ Item 5. ​ Other Information ​ 70 ​ ​ ​ ​ ​ Item 6. ​ Exhibits ​ 71 ​ ​ ​ ​ ​ Signatures ​ 74 ​ ​ ​ 2 Table of Contents GLOSSARY OF TERMS AND ABBREVIAT…
GOSS Gossamer Bio, Inc. 72% million. Receipts pursuant to the Daré RPAs were negligible in 2025. DSUVIA - Talphera Commercial Payment Purchase Agreement In January 2024, we acquired an economic interest in DSUVIA (sufentanil su…
GOSS Gossamer Bio, Inc. 72% Reciprocal relationship from GOSS graph: Reciprocal relationship from XOMA graph: Reciprocal relationship from GOSS graph: Reciprocal relationship from XOMA graph: million. Receipts pursuant to the D…
LGND Ligand Pharmaceuticals Incorporated 72% Reciprocal relationship from LGND graph: Reciprocal relationship from XOMA graph: Reciprocal relationship from LGND graph: Reciprocal relationship from XOMA graph: Reciprocal relationship from LGND g…
LGND Ligand Pharmaceuticals Incorporated 72% Item 4. ​ Mine Safety Disclosures ​ 70 ​ ​ ​ ​ ​ Item 5. ​ Other Information ​ 70 ​ ​ ​ ​ ​ Item 6. ​ Exhibits ​ 71 ​ ​ ​ ​ ​ Signatures ​ 74 ​ ​ ​ 2 Table of Contents GLOSSARY OF TERMS AND ABBREVIAT…
OBDC Blue Owl Capital Corporation 72% Item 4. ​ Mine Safety Disclosures ​ 70 ​ ​ ​ ​ ​ Item 5. ​ Other Information ​ 70 ​ ​ ​ ​ ​ Item 6. ​ Exhibits ​ 71 ​ ​ ​ ​ ​ Signatures ​ 74 ​ ​ ​ 2 Table of Contents GLOSSARY OF TERMS AND ABBREVIAT…
OBDC Blue Owl Capital Corporation 72% Reciprocal relationship from OBDC graph: Reciprocal relationship from XOMA graph: Reciprocal relationship from OBDC graph: Reciprocal relationship from XOMA graph: Reciprocal relationship from OBDC g…
REGN Regeneron Pharmaceuticals, Inc. 72% Item 4. ​ Mine Safety Disclosures ​ 70 ​ ​ ​ ​ ​ Item 5. ​ Other Information ​ 70 ​ ​ ​ ​ ​ Item 6. ​ Exhibits ​ 71 ​ ​ ​ ​ ​ Signatures ​ 74 ​ ​ ​ 2 Table of Contents GLOSSARY OF TERMS AND ABBREVIAT…
REGN Regeneron Pharmaceuticals, Inc. 72% Reciprocal relationship from REGN graph: Reciprocal relationship from XOMA graph: Reciprocal relationship from REGN graph: Reciprocal relationship from XOMA graph: Item 4. ​ Mine Safety Disclosures ​…
TKPHF Takeda Pharmaceutical Company Limited 72% Item 4. ​ Mine Safety Disclosures ​ 70 ​ ​ ​ ​ ​ Item 5. ​ Other Information ​ 70 ​ ​ ​ ​ ​ Item 6. ​ Exhibits ​ 71 ​ ​ ​ ​ ​ Signatures ​ 74 ​ ​ ​ 2 Table of Contents GLOSSARY OF TERMS AND ABBREVIAT…
TKPHF Takeda Pharmaceutical Company Limited 72% Reciprocal relationship from TKPHF graph: Reciprocal relationship from XOMA graph: Item 4. ​ Mine Safety Disclosures ​ 70 ​ ​ ​ ​ ​ Item 5. ​ Other Information ​ 70 ​ ​ ​ ​ ​ Item 6. ​ Exhibits ​ 71 …
TWST Twist Bioscience Corporation 72% Item 4. ​ Mine Safety Disclosures ​ 70 ​ ​ ​ ​ ​ Item 5. ​ Other Information ​ 70 ​ ​ ​ ​ ​ Item 6. ​ Exhibits ​ 71 ​ ​ ​ ​ ​ Signatures ​ 74 ​ ​ ​ 2 Table of Contents GLOSSARY OF TERMS AND ABBREVIAT…
TWST Twist Bioscience Corporation 72% Reciprocal relationship from TWST graph: Reciprocal relationship from XOMA graph: Reciprocal relationship from TWST graph: Reciprocal relationship from XOMA graph: Item 4. ​ Mine Safety Disclosures ​…
XOMAP XOMA Royalty Corporation 72% Reciprocal relationship from XOMAP graph: Reciprocal relationship from XOMA graph: Reciprocal relationship from XOMAP graph: Reciprocal relationship from XOMA graph: ed and outstanding as of March 31…
XOMAP XOMA Royalty Corporation 72% ed and outstanding as of March 31, 2026 and December 31, 2025 ​ ​ — ​ — Common stock, $ 0.0075 par value, 277,333,332 shares authorized, 11,909,854 and 11,858,955 shares issued and outstanding as of …
ZVRA Zevra Therapeutics, Inc. 72% Reciprocal relationship from ZVRA graph: Reciprocal relationship from XOMA graph: Item 4. ​ Mine Safety Disclosures ​ 70 ​ ​ ​ ​ ​ Item 5. ​ Other Information ​ 70 ​ ​ ​ ​ ​ Item 6. ​ Exhibits ​ 71 ​…
ZVRA Zevra Therapeutics, Inc. 72% Item 4. ​ Mine Safety Disclosures ​ 70 ​ ​ ​ ​ ​ Item 5. ​ Other Information ​ 70 ​ ​ ​ ​ ​ Item 6. ​ Exhibits ​ 71 ​ ​ ​ ​ ​ Signatures ​ 74 ​ ​ ​ 2 Table of Contents GLOSSARY OF TERMS AND ABBREVIAT…
CAPITAL-RESOURCES CAPITAL-RESOURCES 62% sed in financing activities of $7.6 million for the three months ended March 31, 2026 was primarily due to principal repayments on our Blue Owl Loan of $6.4 million, payments of dividends on our Seri…
CHECKMATE-PHARMACEUTICALS-INC CHECKMATE-PHARMACEUTICALS-INC 62% (ii) 8.00 % of worldwide net sales of D-Fi (dabocemagene autoficel, also known as FCX-007), and (b) 6.7 % of 20 % of proceeds from a potential Priority Review Voucher if Castle Creek obtains and sell…
OAK-HILL-BIO-LTD OAK-HILL-BIO-LTD 62% million. Receipts pursuant to the Daré RPAs were negligible in 2025. DSUVIA - Talphera Commercial Payment Purchase Agreement In January 2024, we acquired an economic interest in DSUVIA (sufentanil su…
TEVA-PHARMACEUTICAL-INDUSTRIES-LTD TEVA-PHARMACEUTICAL-INDUSTRIES-LTD 62% million. Receipts pursuant to the Daré RPAs were negligible in 2025. DSUVIA - Talphera Commercial Payment Purchase Agreement In January 2024, we acquired an economic interest in DSUVIA (sufentanil su…

XOMA Royalty Corporation Debt Obligations

InstrumentDescriptionConfidenceEvidence
XOMA-DEBT-13671 Warrants outstanding: 19426 90% xbrl warrant detail from xbrl 2023-12-31.
XOMA-DEBT-13672 Xbrl Convertible 90% xbrl convertible detail from xbrl 2011-12-31.
XOMA-DEBT Debt stack $124.7M 90% Market cache reports total debt of $124.7M.

XOMA Royalty Corporation Acquisitions

Acquired EntityNameConfidenceEvidence
XOMA-ACQ-0001193125-26-181885 XOMA Royalty Corporation completed a tender offer to acquire all of Generation Bio's issued and ... 85% XOMA Royalty Corporation completed a tender offer to acquire all of Generation Bio's issued and outstanding shares.
XOMA-ACQ-0001193125-26-042836 XOMA Royalty Corporation completed a tender offer to acquire all of Generation Bio's issued and ... 85% XOMA Royalty Corporation completed a tender offer to acquire all of Generation Bio's issued and outstanding shares.

XOMA Royalty Corporation Ownership

HolderNameConfidenceEvidence
XOMA-OWNER-MORGAN-STANLEY MORGAN STANLEY 90% 13F overlay lists MORGAN STANLEY as top holder; 85 tracked holders.

XOMA Royalty Corporation Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
ELUT Elutia Inc. 100.00 2
DB Deutsche Bank Aktiengesellschaft 100.00 2
GDTC CytoMed Therapeutics Limited 100.00 2
CLLS Cellectis S.A. 100.00 2
CRMD CorMedix Inc. 100.00 2
GOSS Gossamer Bio, Inc. 100.00 1 ['customer']
ALNY Alnylam Pharmaceuticals, Inc. 100.00 2
ACET Adicet Bio, Inc. 100.00 2
ARTV Artiva Biotherapeutics, Inc. 100.00 2
AXSM Axsome Therapeutics, Inc. 100.00 2
BBIO BridgeBio Pharma, Inc. 100.00 2
CLYM Climb Bio, Inc. 100.00 2
GRAL GRAIL, Inc. 100.00 2
TBPH Theravance Biopharma, Inc. 100.00 2
DAWN Day One Biopharmaceuticals Inc 100.00 2
SUPN Supernus Pharmaceuticals, Inc. 100.00 2
EDSA Edesa Biotech, Inc. 100.00 2
AGEN Agenus Inc. 100.00 2
CHRS Coherus Oncology, Inc. 100.00 2
VKTX Viking Therapeutics, Inc. 100.00 2
Browse supply chain intel →

See the full supply chain map, all relationships, and real-time alerts for XOMA Royalty Corporation.

Unlock full XOMA data — View plans →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map
🔐
XOMA
Unlock XOMA Supply Chain Data
Verified relationships include:
AFFITECH-RESEARCH-ASAFFITECH-RESEARCH-ASSupplier92%
AGENUS-INCAGENUS-INCSupplier92%
GENERATION-BIOGENERATION-BIOCustomer92%
RZLTRezolute, Inc.Customer92%
+49 more relationships locked
Subscribe — View plans →
Already a subscriber? Sign in →